New IPO Filing: Alberton Acquisition Corporation Files for a $100M SPAC
by Kristi Marvin on 2018-10-02 at 9:11am

Alberton Acquisition Corporation, filed for a $100 million SPAC IPO this morning with a broad focus that will not be limited by industry or geography.  Alberton is being led by Bin (Ben) Wang, as Chairman and CEO.  Mr. Wang is currently a Managing Director of Eon Capital International Ltd, a Hong Kong-incorporated corporate advisory service company, where he has advised on numerous M&A and project financing transactions.

Alberton’s SPAC structure is similar to Atlantic Acquisition Corp. (another Chardan SPAC) in that its unit does not include a warrant.  It’s a straight one ordinary share plus one right for 1/10 of an ordinary share.  Additionally, Alberton will only have 12 months to find an acquisition.  However, they do have the ability to get two 3-month extensions by contributing $1 million into trust at each extension.

The use of a flat amount of $1 million to extend is a little different than previous structures that have stated they will contribute on a per-share basis to trust.  For instance, Tottenham and Greenland have 12 months as well, but for their extensions they need to contribute $0.10 per share.  However, for a $100 million SPAC, a contribution of $1 million is the same amount, i.e., equivalent to $0.10 per share.

Additionally, the lack of a warrant included in the unit did not seem to hinder Atlantic Acquisition’s IPO, which was the first SPAC to leave them out (if memory serves).  ATAC recently completed their SPAC in twelve months and the share is currently trading at $14.95.  So it will be interesting to see if a unit, with only a right, catches on in future SPACs.

Summary of terms below.

Albertson Acquisition Corporation Summary of Terms:
  • Focus:  General / Broad
  • Size: $100 million
  • 100.0% held in trust ($10.00 per share)
  • $10.00 Unit comprised of one Ordinary Share + 1 Right for 1/10 of one Ordinary Share
    • No Warrants included in this Unit
  • 12 months to complete an acquisition + two 3-month extensions (18 months total)
    • $1 million to be deposited in trust at each extension
  • At-risk Capital: $3.0 million (300,000 Units at $10.00)
  • Underwriter fees: 2.0% + 3.5% deferred

Chardan is sole book-running manager.
White and Williams LLP and Loeb & Loeb LLP are Issuer’s Counsel and Underwriter’s Counsel, respectively.

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved